Want to see RCUS full AI Analyst Report?
Arcus Biosciences (RCUS) Ratios
Arcus Biosciences Ratios
RCUS's free cash flow for Q2 2026 was $-119.00M. For the 2026 fiscal year, RCUS's free cash flow was increased by $0.00 and operating cash flow was $-119.00M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.36 | 4.50 | 4.52 | 5.52 | 7.60 |
| Quick Ratio | 4.36 | 4.50 | 4.52 | 5.52 | 7.60 |
| Cash Ratio | 0.96 | 0.66 | 0.69 | 1.07 | 0.89 |
| Solvency Ratio | -0.68 | -0.41 | -0.47 | -0.38 | 0.08 |
| Operating Cash Flow Ratio | -2.09 | -0.75 | -1.66 | 2.27 | -1.54 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 146.00 | -50.23 |
| Net Current Asset Value | $ 499.00M | $ 351.00M | $ 198.00M | $ 378.00M | $ 511.30M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.05 | 0.01 | 0.09 | 0.08 |
| Debt-to-Equity Ratio | 0.18 | 0.12 | 0.02 | 0.18 | 0.14 |
| Debt-to-Capital Ratio | 0.15 | 0.11 | 0.02 | 0.15 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.14 | 0.09 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.81 | 2.37 | 2.37 | 2.05 | 1.89 |
| Debt Service Coverage Ratio | -41.88 | -67.50 | -148.50 | -51.80 | 11.18 |
| Interest Coverage Ratio | -48.25 | -82.50 | -170.00 | -140.00 | 0.00 |
| Debt to Market Cap | 0.04 | 0.04 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.12 | 0.71 | 0.18 | 1.69 | 1.76 |
| Net Debt to EBITDA | 0.33 | 0.33 | 0.40 | 0.33 | -0.44 |
| Profitability Margins | |||||
| Gross Profit Margin | 95.95% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -139.68% | -108.14% | -255.56% | -235.71% | 14.36% |
| EBITDA Margin | -135.63% | -104.26% | -248.72% | -230.36% | 15.40% |
| Operating Profit Margin | -156.28% | -127.91% | -290.60% | -250.00% | 14.10% |
| Pretax Profit Margin | -142.91% | -109.69% | -257.26% | -237.50% | 14.36% |
| Net Profit Margin | -142.91% | -109.69% | -262.39% | -238.39% | 13.84% |
| Continuous Operations Profit Margin | -142.91% | -110.08% | -262.39% | -238.39% | 13.84% |
| Net Income Per EBT | 100.00% | 100.00% | 101.99% | 100.38% | 96.36% |
| EBT Per EBIT | 91.45% | 85.76% | 88.53% | 95.00% | 101.85% |
| Return on Assets (ROA) | -30.99% | -24.61% | -28.04% | -19.85% | 3.33% |
| Return on Equity (ROE) | -55.94% | -58.35% | -66.45% | -40.64% | 6.30% |
| Return on Capital Employed (ROCE) | -42.51% | -35.71% | -37.32% | -24.31% | 3.79% |
| Return on Invested Capital (ROIC) | -41.91% | -35.26% | -36.88% | -24.24% | 3.64% |
| Return on Tangible Assets | -30.99% | -24.61% | -28.04% | -19.85% | 3.33% |
| Earnings Yield | -13.79% | -21.09% | -21.72% | -17.93% | 1.89% |
| Efficiency Ratios | |||||
| Receivables Turnover | 15.44 | 10.32 | 2.79 | 2.60 | 0.51 |
| Payables Turnover | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 6.17 | 5.49 | 2.29 | 0.83 | 2.79 |
| Asset Turnover | 0.22 | 0.22 | 0.11 | 0.08 | 0.24 |
| Working Capital Turnover Ratio | 0.32 | 0.36 | 0.15 | 0.11 | 0.45 |
| Cash Conversion Cycle | -1509.36 | 35.37 | 131.03 | 140.13 | 711.72 |
| Days of Sales Outstanding | 23.64 | 35.37 | 131.03 | 140.13 | 711.72 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1533.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 23.64 | 35.37 | 131.03 | 140.13 | 711.72 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.49 | -1.89 | -4.14 | 6.08 | -3.69 |
| Free Cash Flow Per Share | -4.51 | -1.95 | -4.46 | 6.00 | -4.07 |
| Dividend Paid and CapEx Coverage Ratio | -241.00 | -28.33 | -12.75 | 73.00 | -9.82 |
| Capital Expenditure Coverage Ratio | -241.00 | -28.33 | -12.75 | 73.00 | -9.82 |
| Operating Cash Flow Coverage Ratio | -4.30 | -2.83 | -27.82 | 3.65 | -2.10 |
| Operating Cash Flow to Sales Ratio | -1.95 | -0.66 | -2.62 | 3.91 | -0.67 |
| Free Cash Flow Yield | -18.91% | -13.12% | -23.35% | 29.01% | -10.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.24 | -4.74 | -4.60 | -5.58 | 52.95 |
| Price-to-Sales (P/S) Ratio | 10.36 | 5.20 | 12.08 | 13.29 | 7.33 |
| Price-to-Book (P/B) Ratio | 4.06 | 2.77 | 3.06 | 2.27 | 3.34 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.29 | -7.62 | -4.28 | 3.45 | -9.94 |
| Price-to-Operating Cash Flow Ratio | -5.31 | -7.89 | -4.62 | 3.40 | -10.96 |
| Price-to-Earnings Growth (PEG) Ratio | -1.52 | 0.19 | -0.39 | 0.01 | -0.39 |
| Enterprise Value Multiple | -7.31 | -4.65 | -4.46 | -5.44 | 47.13 |
| Enterprise Value | 2.45B | 1.25B | 1.30B | 1.40B | 2.78B |
| EV to EBITDA | -7.31 | -4.65 | -4.46 | -5.44 | 47.13 |
| EV to Sales | 9.92 | 4.85 | 11.09 | 12.53 | 7.26 |
| EV to Free Cash Flow | -5.06 | -7.11 | -3.93 | 3.25 | -9.85 |
| EV to Operating Cash Flow | -5.08 | -7.36 | -4.24 | 3.20 | -10.85 |
| Tangible Book Value Per Share | 5.88 | 5.38 | 6.24 | 9.13 | 12.13 |
| Shareholders’ Equity Per Share | 5.88 | 5.38 | 6.24 | 9.13 | 12.13 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | -0.02 | -0.00 | 0.04 |
| Revenue Per Share | 2.30 | 2.86 | 1.58 | 1.56 | 5.52 |
| Net Income Per Share | -3.29 | -3.14 | -4.15 | -3.71 | 0.76 |
| Tax Burden | 1.00 | 1.00 | 1.02 | 1.00 | 0.96 |
| Interest Burden | 1.02 | 1.01 | 1.01 | 1.01 | 1.00 |
| Research & Development to Revenue | 2.12 | 1.74 | 2.91 | 2.57 | 0.67 |
| SG&A to Revenue | 0.45 | 0.47 | 1.00 | 0.93 | 0.19 |
| Stock-Based Compensation to Revenue | 0.24 | 0.29 | 0.62 | 0.00 | 0.14 |
| Income Quality | 1.37 | 0.60 | 1.00 | -1.64 | -4.85 |
Currency in USD